When winter is upon us, we are aware of our shorter days and colder temperatures. Animals have their own adaptations for ...

Collaborating institutions in Taiwan report higher risks of atopic disease among children conceived via assisted reproductive ...

Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...

This week a great and very good man died. Former National Party senator Ron Boswell was not every political and general ...

Trump has insisted that Greenland needs to be brought under US control, arguing that the Danish autonomous territory is ...

Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) ...

The data illustrate that several patients remained on zenocutuzumab well beyond progression, including multiple patients who continued treatment for more than one- or two-years post-progression.

A significant concern, particularly for cysts in the lower jaw, is potential nerve disturbance. The nerve that provides ...

Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...

Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients ...

Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations -- Program will ...

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...